<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20120824142142+02'00'</creation_date><modification_date>D:20120824142142+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-04-273_h_a_dec_5.pdf</pdf_file></head><body><section><header>european commission brussels, 23.8.2012 c(2012)6013 final</header></section><section><header>commission implementing decision of 23.8.2012 
 amending the marketing authorisation granted by decision c(2004)1765 for “lysodren -
 mitotane”, a medicinal product for human use</header><p>(text with eea relevance) (only the french text is authentic)</p></section><section><header>commission implementing decision of 23.8.2012 
 amending the marketing authorisation granted by decision c(2004)1765 for 
 “lysodren - mitotane”, a medicinal product for human use</header><p>(text with eea relevance) (only the french text is authentic) 
 the european commission, 
 having regard to the treaty on the functioning of the european union, 
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a 
 european medicines agency
 1, having regard to commission regulation (ec) no 1234/2008 of 24 november 2008 
 concerning the examination of variations to the terms of marketing authorisations for 
 medicinal products for human use and veterinary medicinal products
 2, and in particular article 17(2) thereof, 
 having regard to directive 2001/83/ec of the european parliament and of the council of 
 6 november 2001 on the community code relating to medicinal products for human use
 3, and in particular article 61(3) thereof, 
 having regard to the notification submitted by laboratoire hra pharma, under article 
 15(1) of regulation (ec) no 1234/2008, 
 whereas: 
 (1)</p><p>the european medicines agency has informed the marketing authorisation 
 holder and the commission of its favourable opinion on the minor variation of 
 type ib, notified between 29 november 2011 and 12 july 2012, and of the need to 
 amend the decision granting the marketing authorisation.</p><p>
 1 oj l 136, 30.4.2004, p. 1. 2 oj l 334, 12.12.2008, p. 7. 3 oj l 311, 28.11.2001, p. 67.</p><p> (2) laboratoire hra pharma has submitted, under article 61(3) of directive 
 2001/83/ec, a notification for changes to an aspect of the labelling or the package 
 leaflet, which is not yet included in decision c(2004)1765 of 28 april 2004. 
 (3)</p><p>the marketing authorisation should be updated and decision c(2004)1765 of 28 
 april 2004 should therefore be amended accordingly. the community register of 
 medicinal products should also be updated. 
 (4)</p><p>for the sake of clarity and transparency, it is appropriate, following the 
 amendment of part or parts of the annexes, to provide for a consolidated version 
 thereof. the annexes to decision c(2004)1765 should therefore be replaced, 
 has adopted this decision: 
 article 1 decision c(2004)1765 is amended as follows: 1) the following notification for a minor variation is added to the marketing 
 authorisation: 
 application number 
 scope (eu numbers affected)</p><p>emea/h/c/521/ib/12 
 c.i.3.a) (eu/1/04/273/001)</p><p>
 2) the following notification for a change to an aspect of the labelling or the package 
 leaflet is added to the marketing authorisation: 
 application number 
 annex (eu numbers affected)</p><p>emea/h/c/521/n/13 
 iiib (eu/1/04/273/001)</p><p>
 3) annex i is replaced by the text set out in annex i to this decision;</p><p>4) annex iii b is replaced by the text set out in annex iii b to this decision.</p><p> article 2 this decision is addressed to laboratoire hra pharma, 15, rue béranger, 75003 paris, france. 
 done at brussels, on 23.8.2012.</p><p>for the commission</p><p>
 paola testori coggi</p><p>
 director-general</p></section></body></xml>